Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
Hervé Tilly, Franck Morschhauser, Nancy L Bartlett, Amitkumar Mehta, Gilles Salles, Corinne Haioun, Javier Munoz, Andy I Chen, Kathryn Kolibaba, Dan Lu, Mark Yan, Elicia Penuel, Jamie Hirata, Calvin Lee, Jeff P Sharman
BACKGROUND: Polatuzumab vedotin, an antibody-drug conjugate targeting the CD79b component of the B-cell receptor, has demonstrated activity as a single agent and in combination with rituximab in relapsed or refractory diffuse large B-cell lymphoma. In this study, we evaluated the safety and preliminary activity of polatuzumab vedotin in combination with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, and prednisone (CHP) in patients with previously untreated diffuse large B-cell lymphoma...
May 14, 2019: Lancet Oncology
#2
Andrés J M Ferreri
No abstract text is available yet for this article.
May 14, 2019: Lancet Oncology
#3
Paul G Richardson, Albert Oriol, Meral Beksac, Anna Marina Liberati, Monica Galli, Fredrik Schjesvold, Jindriska Lindsay, Katja Weisel, Darrell White, Thierry Facon, Jesus San Miguel, Kazutaka Sunami, Peter O'Gorman, Pieter Sonneveld, Pawel Robak, Sergey Semochkin, Steve Schey, Xin Yu, Thomas Doerr, Amine Bensmaine, Tsvetan Biyukov, Teresa Peluso, Mohamed Zaki, Kenneth Anderson, Meletios Dimopoulos
BACKGROUND: As lenalidomide becomes increasingly established for upfront treatment of multiple myeloma, patients refractory to this drug represent a population with an unmet need. The combination of pomalidomide, bortezomib, and dexamethasone has shown promising results in phase 1/2 trials of patients with relapsed or refractory multiple myeloma. We aimed to assess the efficacy and safety of this triplet regimen in patients with relapsed or refractory multiple myeloma who previously received lenalidomide...
May 13, 2019: Lancet Oncology
#4
Francesca Gay, Roberto Mina
No abstract text is available yet for this article.
May 13, 2019: Lancet Oncology
#5
(no author information available yet)
No abstract text is available yet for this article.
May 10, 2019: Lancet Oncology
#6
(no author information available yet)
No abstract text is available yet for this article.
May 10, 2019: Lancet Oncology
#7
Ryan Varatharajah
No abstract text is available yet for this article.
May 10, 2019: Lancet Oncology
#8
Elizabeth Gourd
No abstract text is available yet for this article.
May 10, 2019: Lancet Oncology
#9
Saffya Benniche
No abstract text is available yet for this article.
May 10, 2019: Lancet Oncology
#10
Robert Stirrups
No abstract text is available yet for this article.
May 10, 2019: Lancet Oncology
#11
Nicolas Penel, Yves-Marie Robin, Jean-Yves Blay
No abstract text is available yet for this article.
May 8, 2019: Lancet Oncology
#12
Breelyn A Wilky, Matteo M Trucco, Ty K Subhawong, Vaia Florou, Wungki Park, Deukwoo Kwon, Eric D Wieder, Despina Kolonias, Andrew E Rosenberg, Darcy A Kerr, Efrosyni Sfakianaki, Mark Foley, Jaime R Merchan, Krishna V Komanduri, Jonathan C Trent
BACKGROUND: VEGF promotes an immunosuppressive microenvironment and contributes to immune checkpoint inhibitor resistance in cancer. We aimed to assess the activity of the VEGF receptor tyrosine-kinase inhibitor axitinib plus the anti-PD-1 immune checkpoint inhibitor pembrolizumab in patients with sarcoma. METHODS: This single-centre, single-arm, phase 2 trial was undertaken at a tertiary care academic medical centre in Miami, FL, USA, and participants were recruited from all over the USA and internationally...
May 8, 2019: Lancet Oncology
#13
Brooke E Wilson, Susannah Jacob, Mei Ling Yap, Jacques Ferlay, Freddie Bray, Michael B Barton
BACKGROUND: The incidence of cancer (excluding non-melanomatous skin cancers) is projected to rise from 17·0 million to 26·0 million between 2018 and 2040. A large proportion of these patients would be likely to derive benefit from chemotherapy, but no studies so far have quantified current and projected global chemotherapy demands. We aimed to estimate changes in national, regional, and global demands for first-course chemotherapy and the cancer physician workforce between 2018 and 2040 if all patients were treated according to best-practice evidence-based guidelines...
May 8, 2019: Lancet Oncology
#14
Sophia Zackrisson
No abstract text is available yet for this article.
May 8, 2019: Lancet Oncology
#15
Melina Arnold, Isabelle Soerjomataram
No abstract text is available yet for this article.
May 8, 2019: Lancet Oncology
#16
Solveig Hofvind, Åsne S Holen, Hildegunn S Aase, Nehmat Houssami, Sofie Sebuødegård, Tron A Moger, Ingfrid S Haldorsen, Lars A Akslen
BACKGROUND: Digital breast tomosynthesis is an advancement of mammography, and has the potential to overcome limitations of standard digital mammography. This study aimed to compare first-generation digital breast tomo-synthesis including two-dimensional (2D) synthetic mammograms versus digital mammography in a population-based screening programme. METHODS: BreastScreen Norway offers all women aged 50-69 years two-view (craniocaudal and mediolateral oblique) mammographic screening every 2 years and does independent double reading with consensus...
May 8, 2019: Lancet Oncology
#17
Ignace Vergote, Giovanni Scambia, David M O'Malley, Ben Van Calster, Sang-Yoon Park, Josep M Del Campo, Werner Meier, Aristotelis Bamias, Nicoletta Colombo, Robert M Wenham, Al Covens, Christian Marth, Mansoor Raza Mirza, Judith R Kroep, Haijun Ma, Cheryl A Pickett, Bradley J Monk
BACKGROUND: Angiopoietin 1 and 2 regulate angiogenesis and vascular remodelling by interacting with the tyrosine kinase receptor Tie2, and inhibition of angiogenesis has shown promise in the treatment of ovarian cancer. We aimed to assess whether trebananib, a peptibody that inhibits binding of angiopoietin 1 and 2 to Tie2, improved progression-free survival when added to carboplatin and paclitaxel as first-line therapy in advanced epithelial ovarian, primary fallopian tube, or peritoneal cancer in a phase 3 clinical trial...
May 7, 2019: Lancet Oncology
#18
Angeles Alvarez Secord
No abstract text is available yet for this article.
May 7, 2019: Lancet Oncology
#19
Elizabeth Gourd
No abstract text is available yet for this article.
May 3, 2019: Lancet Oncology
#20
Manjulika Das
No abstract text is available yet for this article.
May 3, 2019: Lancet Oncology
Fetching more papers... 
